SI2368999T1 - Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe - Google Patents

Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe

Info

Publication number
SI2368999T1
SI2368999T1 SI200831200T SI200831200T SI2368999T1 SI 2368999 T1 SI2368999 T1 SI 2368999T1 SI 200831200 T SI200831200 T SI 200831200T SI 200831200 T SI200831200 T SI 200831200T SI 2368999 T1 SI2368999 T1 SI 2368999T1
Authority
SI
Slovenia
Prior art keywords
amino acid
alkaline phosphatase
kits
methods
bone targeted
Prior art date
Application number
SI200831200T
Other languages
English (en)
Slovenian (sl)
Inventor
Philippe Crine
Guy Boileau
Thomas P. Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Original Assignee
Alexion Pharma Holding,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Holding, filed Critical Alexion Pharma Holding,
Publication of SI2368999T1 publication Critical patent/SI2368999T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
SI200831200T 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe SI2368999T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
EP11004496.3A EP2368999B1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (1)

Publication Number Publication Date
SI2368999T1 true SI2368999T1 (sl) 2014-07-31

Family

ID=40001639

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200831200T SI2368999T1 (sl) 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe
SI200831780A SI2662448T1 (sl) 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200831780A SI2662448T1 (sl) 2007-05-11 2008-05-12 Alkalna fosfataza, ki cilja kosti, kompleti in načini njihove uporabe

Country Status (25)

Country Link
US (1) US20100297119A1 (cg-RX-API-DMAC7.html)
EP (3) EP2662448B1 (cg-RX-API-DMAC7.html)
JP (1) JP5732603B2 (cg-RX-API-DMAC7.html)
AT (1) ATE536413T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008250945B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0811198B8 (cg-RX-API-DMAC7.html)
CA (1) CA2687001C (cg-RX-API-DMAC7.html)
CY (1) CY2016005I2 (cg-RX-API-DMAC7.html)
DE (1) DE202008018131U1 (cg-RX-API-DMAC7.html)
DK (3) DK2158319T3 (cg-RX-API-DMAC7.html)
ES (3) ES2380546T3 (cg-RX-API-DMAC7.html)
FR (1) FR16C0007I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20140416T1 (cg-RX-API-DMAC7.html)
HU (2) HUE031655T2 (cg-RX-API-DMAC7.html)
IL (1) IL202057A0 (cg-RX-API-DMAC7.html)
LT (1) LTC2368999I2 (cg-RX-API-DMAC7.html)
LU (1) LU92976I2 (cg-RX-API-DMAC7.html)
ME (1) ME01828B (cg-RX-API-DMAC7.html)
NL (1) NL300798I2 (cg-RX-API-DMAC7.html)
NO (1) NO2016002I2 (cg-RX-API-DMAC7.html)
PL (3) PL2662448T3 (cg-RX-API-DMAC7.html)
PT (3) PT2662448T (cg-RX-API-DMAC7.html)
RS (1) RS53302B (cg-RX-API-DMAC7.html)
SI (2) SI2368999T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008138131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2348114T1 (sl) 2004-04-21 2018-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
MX394440B (es) 2007-06-01 2025-03-24 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
CA2797865A1 (en) 2010-04-30 2011-11-03 Alexion Pharma International Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
TR201906652T4 (tr) 2010-07-28 2019-05-21 Gliknik Inc Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104718223A (zh) 2012-08-20 2015-06-17 格利克尼克股份有限公司 具有抗原结合和多价FCγ受体结合活性的分子
RU2683635C2 (ru) 2014-01-24 2019-03-29 Ам-Фарма Б.В. Химерные белки, подобные щелочной фосфатазе
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
DK3325011T6 (da) 2015-07-24 2023-05-15 Gliknik Inc Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding
CA2993358A1 (en) * 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) * 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173413A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
EP3474886B1 (en) 2016-06-27 2021-08-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP7649624B2 (ja) * 2016-11-30 2025-03-21 パーデュー リサーチ ファウンデーション 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
EP3600383A4 (en) * 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 糖タンパク質の製造
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3965805A4 (en) 2019-05-06 2023-01-25 Synthetic Biologics, Inc. ALKALINE PHOSPHATE BASED ONCOLOGICAL TREATMENTS
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
JP2023510195A (ja) 2020-01-03 2023-03-13 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 歯周の健康を促進するために局所投与されるtnap
KR20230117327A (ko) * 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
US12083169B2 (en) * 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4581048A2 (en) * 2022-08-31 2025-07-09 University of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP1232276B8 (en) 1999-11-16 2007-06-27 Genzyme Corporation Vectors and transgenes with regulatory elements for gene delivery to the liver
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
SI2348114T1 (sl) * 2004-04-21 2018-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006039480A2 (en) * 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
BRPI0515819A (pt) 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado

Also Published As

Publication number Publication date
PL2158319T4 (pl) 2016-04-29
DK2368999T3 (da) 2014-05-26
WO2008138131A1 (en) 2008-11-20
JP2010526543A (ja) 2010-08-05
NL300798I1 (cg-RX-API-DMAC7.html) 2016-03-16
AU2008250945B2 (en) 2013-12-12
BRPI0811198A8 (pt) 2018-08-14
BRPI0811198A2 (pt) 2014-10-21
WO2008138131A9 (en) 2009-08-06
ATE536413T1 (de) 2011-12-15
CY2016005I1 (el) 2016-08-31
EP2368999A1 (en) 2011-09-28
ME01828B (me) 2014-12-20
FR16C0007I1 (cg-RX-API-DMAC7.html) 2016-04-15
HK1191372A1 (en) 2014-07-25
EP2368999B1 (en) 2014-03-12
IL202057A0 (en) 2011-08-01
EP2158319A4 (en) 2010-07-21
LTC2368999I2 (lt) 2017-09-25
BRPI0811198B1 (pt) 2021-03-09
HRP20140416T1 (hr) 2014-06-20
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
DK2158319T3 (da) 2012-03-19
US20100297119A1 (en) 2010-11-25
ES2380546T3 (es) 2012-05-16
BR122019000505B1 (pt) 2022-01-18
HK1141047A1 (en) 2010-10-29
CA2687001A1 (en) 2008-11-20
EP2158319A1 (en) 2010-03-03
SI2662448T1 (sl) 2017-05-31
PL2662448T3 (pl) 2017-07-31
JP5732603B2 (ja) 2015-06-10
RS53302B (sr) 2014-08-29
DK2662448T3 (en) 2017-03-20
EP2662448B1 (en) 2016-12-21
PT2158319E (pt) 2012-03-06
FR16C0007I2 (fr) 2017-01-27
PL2368999T3 (pl) 2014-08-29
WO2008138131A4 (en) 2008-12-31
AU2008250945A2 (en) 2009-12-24
PL2158319T3 (pl) 2012-05-31
ES2619332T3 (es) 2017-06-26
NL300798I2 (cg-RX-API-DMAC7.html) 2016-03-16
LU92976I2 (en) 2016-04-11
PT2368999E (pt) 2014-05-26
CA2687001C (en) 2019-02-12
EP2158319B1 (en) 2011-12-07
CY2016005I2 (el) 2016-08-31
HUS1600005I1 (hu) 2016-02-29
ES2471915T3 (es) 2014-06-27
LTPA2016004I1 (lt) 2016-02-25
PT2662448T (pt) 2017-03-29
HK1162589A1 (en) 2012-08-31
NO2016002I1 (no) 2016-02-02
BR122019000505A2 (pt) 2021-12-14
BRPI0811198B8 (pt) 2021-05-25
DE202008018131U1 (de) 2011-12-30
NO2016002I2 (no) 2016-02-02
AU2008250945A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
NL300798I1 (cg-RX-API-DMAC7.html)
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
BRPI0414598A (pt) indóis substituìdos
HRP20090245T1 (en) Pyy agonists and uses thereof
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
CY1109984T1 (el) Παραλλαγες gla πεδιου παραγοντα vii ή viia
MX347545B (es) Polipeptidos con actividad xilanasa.
HUP0101317A2 (hu) Módosított VIII-as faktor
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
SE0302103D0 (sv) Xylanases with enhanced thermophilicity and alkalophilicity
DK2084198T3 (da) Beklædningssammensætning
EP2004352A4 (en) AMINO ACID SUPPLEMENT FOR PEPTIDE CONSTRUCTIONS
ES2573462T3 (es) Polipéptidos de PH20 soluble extendida y usos de los mismos
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
MY150639A (en) T cell adhesion molecule and antibody thereto
TW200731985A (en) A composition for wound healing and use thereof